{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:11Z","timestamp":1786480211066,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Renal adverse events occurred in 34.7% of patients with bevacizumab-treated ovarian cancer, with hypertension being the most frequent manifestation.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Pre-existing hypertension was the only independent risk factor for developing renal adverse events during bevacizumab therapy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The occurrence of renal adverse events was independently associated with improved overall survival, suggesting effective vascular endothelial growth factor pathway inhibition.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor-A, is a cornerstone in ovarian cancer (OC). Bevacizumab is associated with renal adverse events, including hypertension (HTN), proteinuria, and AKI. The incidence, risk factors, and prognostic effect of these renal events remain poorly defined. This study aimed to determine the incidence, risk factors, and association with mortality of renal events in patients with OC treated with bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective single-center study including 147 patients with OC treated with bevacizumab between 2011 and 2023. Renal events were defined as new-onset or worsening HTN (grade \u22652), proteinuria (grade \u22652), and\/or AKI, as per Common Terminology Criteria for Adverse Events v5.0 and Kidney Disease Improving Global Outcomes guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median follow-up of 52 months, 34.7% of patients developed a renal event, most commonly HTN (27.9%), followed by proteinuria (6.8%) and AKI (6.8%). Only a history of HTN was identified as an independent risk factor for renal event (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0078). Importantly, patients with renal events had significantly longer survival compared with those who did not (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0243). In the multivariate analysis, the occurrence of a renal event emerged as a protective factor against mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, renal events occurred in 34.7% of bevacizumab-treated patients. HTN was a risk factor for renal event, but renal events seemed to be a protective factor against mortality. Rather than signaling harm, their presence may reflect effective Vascular endothelial growth factor pathway inhibition and greater antitumor response. Routine monitoring and early nephrological management of HTN, proteinuria, and AKI are essential to optimize treatment continuity and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001137","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:00:30Z","timestamp":1769187630000},"page":"1086-1094","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab-Associated Renal Adverse Events Signal Better Prognosis in Ovarian Cancer"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5154-7898","authenticated-orcid":false,"given":"Cristina","family":"Riaza","sequence":"first","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-1845","authenticated-orcid":false,"given":"Marta","family":"\u00c1lvarez-Nadal","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-3306","authenticated-orcid":false,"given":"Antonio","family":"Casado","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, San Carlos Clinical University Hospital, EURACAN Referral Centre, UCM, IdissC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-9787","authenticated-orcid":false,"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, San Carlos Clinical University Hospital, EURACAN Referral Centre, UCM, IdissC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-5360","authenticated-orcid":false,"given":"Marta","family":"Calvo","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-1676","authenticated-orcid":false,"given":"Antolina","family":"Rodr\u00edguez-Moreno","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rivero","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-9729","authenticated-orcid":false,"given":"Ana I.","family":"S\u00e1nchez-Fructuoso","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"},{"name":"Department of Medicine, Complutense University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Garc\u00eda-Carro","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital, IdISSC, Madrid, Spain"},{"name":"Biomedical Research Institute of San Carlos Clinical University Hospital, Madrid, Spain"},{"name":"Department of Medicine, Complutense University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1-20260601","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"26","key":"B3-20260601","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med."},{"key":"B4-20260601","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.biopha.2018.03.061","article-title":"The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: a review","volume":"102","author":"Chellappan","year":"2018","journal-title":"Biomed Pharmacother."},{"issue":"2","key":"B6-20260601","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B7-20260601","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.3390\/jcm11102915","article-title":"Kidney biopsy in patients with cancer along the last decade: a multicenter study","volume":"11","author":"Bolufer","year":"2022","journal-title":"J Clin Med."},{"issue":"2","key":"B8-20260601","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B10-20260601","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12882-022-02936-y","article-title":"VEGFA promotes the occurrence of PLA2R-associated idiopathic membranous nephropathy by angiogenesis via the PI3K\/AKT signalling pathway","volume":"23","author":"Ke","year":"2022","journal-title":"BMC Nephrol."},{"issue":"11","key":"B11-20260601","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med."},{"issue":"24","key":"B12-20260601","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"B13-20260601","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ekir.2024.03.005","article-title":"Risk factors for severe hypertension and proteinuria after treatment with vascular endothelial growth factor signaling pathway inhibitors among patients with cancer","volume":"9","author":"Hanna","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B14-20260601","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-020-03404-z","article-title":"Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients","volume":"147","author":"Carvalho","year":"2020","journal-title":"J Neurooncol."},{"issue":"1","key":"B16-20260601","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"issue":"8","key":"B17-20260601","doi-asserted-by":"crossref","first-page":"e0289950","DOI":"10.1371\/journal.pone.0289950","article-title":"Bevacizumab-induced proteinuria and its association with antihypertensive drugs: a retrospective cohort study using a Japanese administrative database","volume":"18","author":"Kiyomi","year":"2023","journal-title":"PLoS One."},{"issue":"15_suppl l","key":"B18-20260601","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/jco.2011.29.15_suppl.2021","article-title":"The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM)","volume":"29","author":"Nangia","year":"2011","journal-title":"J Clin Oncol."},{"issue":"4","key":"B19-20260601","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1248\/bpb.b17-00605","article-title":"Hypertension and proteinuria as predictive factors of effects of bevacizumab on advanced breast cancer in Japan","volume":"41","author":"Tanaka","year":"2018","journal-title":"Biol Pharm Bull."},{"issue":"9","key":"B20-20260601","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","article-title":"An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity","volume":"16","author":"Mir","year":"2011","journal-title":"Oncologist."},{"issue":"6","key":"B21-20260601","first-page":"629","article-title":"Advanced lung cancer in the older patient: is there a role for bevacizumab?","volume":"4","author":"Marr","year":"2012","journal-title":"J Thorac Dis."},{"issue":"5","key":"B22-20260601","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/ndt\/gfab034","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Garc\u00eda-Carro","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B23-20260601","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American heart association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension."},{"issue":"7","key":"B24-20260601","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ Res."},{"issue":"7","key":"B25-20260601","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: a critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget."},{"issue":"5","key":"B26-20260601","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol."},{"issue":"4","key":"B27-20260601","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fphar.2019.00426","article-title":"Bevacizumab dose affects the severity of adverse events in gynecologic malignancies","volume":"10","author":"Lee","year":"2019","journal-title":"Front Pharmacol."},{"issue":"5","key":"B28-20260601","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:43Z","timestamp":1786478263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001137"}},"subtitle":["A Double-Edged Vascular Endothelial Growth Factor Inhibition"],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001137","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-10-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}